AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10682963 — intervention group
Group type: EXPERIMENTAL
Intervention: Scanning laser polarimetry
Number of subjects: 78
Study 10682963 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 78
Study 10682963 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual function measurements
Number of subjects: 78
Study 10682963 — intervention group
Group type: EXPERIMENTAL
Intervention: Retinal nerve fiber layer structural measurements
Number of subjects: 78
Study 9052110 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward-based educational teaching package
Number of subjects: 0
Study 9052110 — intervention group
Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 0
Study 8286801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin staggered with calcium carbonate
Number of subjects: 12
Study 8286801 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin alone
Number of subjects: 12
Study 3667020 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultralong exercise (120 km march) for 24 hours
Number of subjects: 15
Study 29722791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NEPA (fosnetupitant 235 mg plus PALO 0.25 mg)
Number of subjects: 404
Study 29722791 — intervention group
Group type: COMPARATOR
Intervention: Oral NEPA (netupitant 300 mg plus PALO 0.50 mg)
Number of subjects: 404
Study 29722791 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous NEPA
Number of subjects: 404
Study 29722791 — intervention group
Group type: COMPARATOR
Intervention: Oral NEPA
Number of subjects: 404
Study 27382926 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute Resistance Exercise (RE)
Number of subjects: 35
Study 27382926 — intervention group
Group type: COMPARATOR
Intervention: Reading session (Control)
Number of subjects: 35
Study 24700136 — intervention group
Group type: EXPERIMENTAL
Intervention: Real dry needling
Number of subjects: 84
Study 24700136 — intervention group
Group type: COMPARATOR
Intervention: Sham dry needling
Number of subjects: 84
Study 24005613 — intervention group
Group type: EXPERIMENTAL
Intervention: PLD 50 mg/m² q28 and vandetanib 100 mg/d po
Number of subjects: 15
Study 21505208 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM) group
Number of subjects: 0
Study 21505208 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18281190 — intervention group
Group type: EXPERIMENTAL
Intervention: One session intervention focused on increasing motivation to quit smoking and reducing anxiety sensitivity
Number of subjects: 96
Study 18281190 — intervention group
Group type: COMPARATOR
Intervention: Health information control condition
Number of subjects: 96
Study 16423739 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual presentation
Number of subjects: 0
Study 16423739 — intervention group
Group type: COMPARATOR
Intervention: Auditory-only presentation
Number of subjects: 0
Study 12601765 — intervention group
Group type: EXPERIMENTAL
Intervention: INFLUSOME-VAC
Number of subjects: 73
Study 12601765 — intervention group
Group type: COMPARATOR
Intervention: Commercial subunit vaccine
Number of subjects: 73
Study 12601765 — intervention group
Group type: COMPARATOR
Intervention: Commercial split virion vaccine
Number of subjects: 73
Study 10870147 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill test
Number of subjects: 30
Study 10870147 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicycle ergometer test
Number of subjects: 30
Study 10870147 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper extremity ergometer test
Number of subjects: 30
Study 9357387 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 100 mg
Number of subjects: 14
Study 9357387 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorzoxazone 250 mg
Number of subjects: 14
Study 9357387 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 100 mg
Number of subjects: 14
Study 9357387 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquin 10 mg
Number of subjects: 14
Study 9357387 — intervention group
Group type: EXPERIMENTAL
Intervention: Mephenytoin 100 mg
Number of subjects: 14
Study 8387346 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (etoposide, epirubicin, and cis-platinum, days 1-3, every 21 days)
Number of subjects: 21
Study 8387346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by rhGM‐CSF (10 micrograms/kg/day s.c., days 4-14)
Number of subjects: 21
Study 8387346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy preceded and followed by rhGM‐CSF (days -17 to -7 for priming, days 4-14 for rescue)
Number of subjects: 21
Study 8387346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus rhGM‐CSF rescue
Number of subjects: 21
Study 8387346 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 21
Study 8387346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy followed by rhGM‐CSF
Number of subjects: 21
Study 8387346 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy preceded and followed by rhGM‐CSF
Number of subjects: 21
Study 3523796 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol 200 mg plus hydrochlorothiazide 12.5 mg (SDX)
Number of subjects: 50
Study 3523796 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg (HCT)
Number of subjects: 50
Study 31727672 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive virtual presence technology (remote assistance via smartphones)
Number of subjects: 1476
Study 31727672 — intervention group
Group type: COMPARATOR
Intervention: Live technicians (on-site assistance)
Number of subjects: 1476
Study 30518400 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic care (spinal manipulation) for 4 weeks
Number of subjects: 110
Study 30518400 — intervention group
Group type: COMPARATOR
Intervention: Waiting list (control group) for 4 weeks
Number of subjects: 110
Study 27259669 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care programme (one annual comprehensive check-up at the outpatient clinic and three quarterly visits at the general practitioners' office)
Number of subjects: 140
Study 27259669 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared care programme
Number of subjects: 140
Study 27259669 — intervention group
Group type: COMPARATOR
Intervention: Control group (four quarterly visits at the outpatient clinic, including an annual comprehensive check-up)
Number of subjects: 140
Study 25713647 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intensity with blood flow restriction (LIBFR)
Number of subjects: 14
Study 25713647 — intervention group
Group type: COMPARATOR
Intervention: Moderate intensity (MI, 50%-1RM)
Number of subjects: 14
Study 22535148 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 250
Study 21226439 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-voice (MV) group (n = 23) listening to a recording of their mothers' voices during the perioperative period
Number of subjects: 46
Study 21226439 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 23) wearing headphones with no auditory stimulation
Number of subjects: 46
Study 18665167 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan 180 mg m‐2 and cetuximab 500 mg m‐2 q2w
Number of subjects: 40
Study 20813681 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg Lornoxicam (L8 group)
Number of subjects: 45
Study 20813681 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 mg Lornoxicam (L16 group)
Number of subjects: 45
Study 20813681 — intervention group
Group type: COMPARATOR
Intervention: 4 ml saline (NS group)
Number of subjects: 45
Study 16281728 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable rigid dressing (RRD)
Number of subjects: 50
Study 11897411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal powder form of glucagon mixed with microcrystalline cellulose at a ratio of 1:69
Number of subjects: 0
Study 11897411 — intervention group
Group type: COMPARATOR
Intervention: Spray solutions of glucagon including 1.5% sodium glycocholate
Number of subjects: 0
Study 11897411 — intervention group
Group type: COMPARATOR
Intervention: Spray solutions of glucagon including 1% sodium caprate
Number of subjects: 0
Study 9600795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1600 mg/day
Number of subjects: 74
Study 9600795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 2400 mg/day
Number of subjects: 74
Study 9600795 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 800 mg/day
Number of subjects: 74
Study 9600795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 8027622 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intraperitoneal 5‐fluorouracil (5‐FU, 500 mg/m2/day) and intravenous leucovorin (60 mg/m2/day)
Number of subjects: 50
Study 8027622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 2731750 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g qds (n = 24)
Number of subjects: 46
Study 2731750 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 200 mg tds and 400 mg nocte (n = 22)
Number of subjects: 46
Study 2731750 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 1 g bd during maintenance
Number of subjects: 46
Study 2731750 — intervention group
Group type: EXPERIMENTAL
Intervention: cimetidine 400 mg nocte during maintenance
Number of subjects: 46
Study 2731750 — intervention group
Group type: COMPARATOR
Intervention: Control group (20 age and sex matched controls)
Number of subjects: 46
Study 790548 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoprofen (150 mg daily in 3 doses of 50 mg)
Number of subjects: 9
Study 790548 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30690446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogen (CEE) plus 100 mg micronized progesterone (MP)
Number of subjects: 123
Study 30690446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg CEE daily plus 100 mg MP
Number of subjects: 123
Study 30690446 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg CEE daily plus 10 mg dydrogesterone (DHG)
Number of subjects: 123
Study 29505549 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralipid postconditioning (ILPC) - intravenous infusion of 20% intralipid (2 mL/kg) just 10 minutes before aortic cross-unclamping
Number of subjects: 69
Study 29505549 — intervention group
Group type: COMPARATOR
Intervention: Normal saline - equivalent volume to ILPC group
Number of subjects: 69
Study 27075438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine administration
Number of subjects: 0
Study 27075438 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration
Number of subjects: 0
Study 25012422 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25mg oral haloperidol daily for 7 days, followed by placebo for 4 weeks
Number of subjects: 48
Study 25012422 — intervention group
Group type: COMPARATOR
Intervention: Placebo throughout the trial
Number of subjects: 48
Study 22724108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal atmospheric pressure plasma (APP) treatment
Number of subjects: 0
Study 22724108 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonthermal atmospheric pressure plasma (APP) treatment at the highest input voltage
Number of subjects: 0
Study 22724108 — intervention group
Group type: COMPARATOR
Intervention: Negative control group
Number of subjects: 0
Study 20460331 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to community fall prevention services
Number of subjects: 204
Study 20460331 — intervention group
Group type: COMPARATOR
Intervention: Standard medical and social care
Number of subjects: 204
Study 17510742 — intervention group
Group type: EXPERIMENTAL
Intervention: Open haemorrhoidectomy
Number of subjects: 686
Study 17510742 — intervention group
Group type: COMPARATOR
Intervention: Closed haemorrhoidectomy
Number of subjects: 686
Study 15777444 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral misoprostol (400 microg)
Number of subjects: 90
Study 15777444 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (800 microg)
Number of subjects: 90
Study 15777444 — intervention group
Group type: COMPARATOR
Intervention: Standard care (no cervical priming agent)
Number of subjects: 90
Study 12452759 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of salmeterol to low-dose fluticasone propionate
Number of subjects: 0
Study 12452759 — intervention group
Group type: COMPARATOR
Intervention: Increasing the dose of fluticasone propionate
Number of subjects: 0
Study 10036846 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 percent carbamide peroxide gel
Number of subjects: 15
Study 8926595 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg bisoprolol once daily for three weeks
Number of subjects: 60
Study 8926595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2046107 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (antihypertensive drug treatment with chlorthalidone and atenolol)
Number of subjects: 4736
Study 2046107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study 2046107 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment
Number of subjects: 4736
Study 6786204 — intervention group
Group type: EXPERIMENTAL
Intervention: Three different estrogen‐progestin regimens
Number of subjects: 0
Study 6786204 — intervention group
Group type: COMPARATOR
Intervention: Estrogen at half the treatment dose
Number of subjects: 0
Study 30885242 — intervention group
Group type: EXPERIMENTAL
Intervention: NaldebainÂ® (nalbuphine sebacate) intramuscularly 24 Â± 12 h prior to surgery
Number of subjects: 110
Study 30885242 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl through 48 h postsurgery
Number of subjects: 110
Study 30885242 — intervention group
Group type: EXPERIMENTAL
Intervention: NaldebainÂ® (nalbuphine sebacate)
Number of subjects: 110
Study 30885242 — intervention group
Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl
Number of subjects: 110
Study 27913279 — intervention group
Group type: EXPERIMENTAL
Intervention: Low abrasivity anti-sensitivity dentifrice (1% alumina and 5% sodium tripolyphosphate)
Number of subjects: 29
Study 27913279 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultra-low abrasivity non-alumina dentifrice (5% sodium tripolyphosphate)
Number of subjects: 29
Study 27913279 — intervention group
Group type: COMPARATOR
Intervention: Higher abrasivity daily-use whitening dentifrice
Number of subjects: 29
Study 27913279 — intervention group
Group type: COMPARATOR
Intervention: Water
Number of subjects: 29
Study 26474657 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 53
Study 26474657 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 53
Study 27129124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril oral solution (1 mg/mL)
Number of subjects: 0
Study 27129124 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril oral solution with a high-fat meal
Number of subjects: 0
Study 27129124 — intervention group
Group type: COMPARATOR
Intervention: Reference listed drug (RLD) tablet
Number of subjects: 0
Study 23021694 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 × 10 criteria
Number of subjects: 143
Study 23021694 — intervention group
Group type: COMPARATOR
Intervention: 15 × 15 criteria
Number of subjects: 143
Study 19718777 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) administration
Number of subjects: 0
Study 19718777 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial neural networks (ANNs) analysis of LRG and IGF‐I data
Number of subjects: 0
Study 19718777 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiver operator characteristic (ROC) analysis
Number of subjects: 0
Study 17043680 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Delta(9)-tetrahydrocannabinol (THC)
Number of subjects: 25
Study 17043680 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal THC-hemisuccinate (THC-HS)
Number of subjects: 25
Study 17043680 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 15188105 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative rehabilitation advice reinforced by a patient information booklet
Number of subjects: 35
Study 15188105 — intervention group
Group type: COMPARATOR
Intervention: Standard pathway of care
Number of subjects: 35
Study 12506472 — intervention group
Group type: EXPERIMENTAL
Intervention: cisplatin (CDDP) 5 mg/body/day (i.v.) plus 5‐FU 300 mg/body/day (cvi) day 1‐5 for 6 weeks, followed by UFT 200 mg (as tegafur) x 2/day for as long as possible
Number of subjects: 190
Study 12506472 — intervention group
Group type: COMPARATOR
Intervention: UFT only administered after surgery as long as possible
Number of subjects: 190
Study 9719743 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 30 mg/kg intravenously 90 minutes prior to induction of anaesthesia (group 1)
Number of subjects: 30
Study 9719743 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 30
Study 8573222 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentalong 50 mg tablets (2 tablets per dose)
Number of subjects: 24
Study 8573222 — intervention group
Group type: COMPARATOR
Intervention: Aqueous suspension prepared from 25% PETN/lactose trituration
Number of subjects: 24
Study 2809002 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (6 mg/kg body weight over 15 min)
Number of subjects: 8
Study 2809002 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 ml of saline solution over 15 min)
Number of subjects: 8
Study 365072 — intervention group
Group type: EXPERIMENTAL
Intervention: tranexamic acid, 4 gm per day for ten consecutive days
Number of subjects: 51
Study 365072 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 51
Study 31305500 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based curriculum
Number of subjects: 24
Study 31305500 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 24
Study 30628566 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages to HWs on malaria case management
Number of subjects: 105
Study 30628566 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messages to HWs on malaria, pneumonia, and diarrhea case management
Number of subjects: 105
Study 30628566 — intervention group
Group type: COMPARATOR
Intervention: Control arm (no messages)
Number of subjects: 105
Study 30628566 — intervention group
Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 105
Study 28215900 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 245
Study 28215900 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 245
Study 28215900 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 245
Study 28215900 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 245
Study 25477272 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative study exploring pregnancy intention and planning through semistructured interviews.
Number of subjects: 66
Study 25477272 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative analysis of narratives using content analysis and constant comparison method.
Number of subjects: 66
Study 24075770 — intervention group
Group type: EXPERIMENTAL
Intervention: MGL-3196 (doses of 50 to 200 mg per day)
Number of subjects: 0
Study 24075770 — intervention group
Group type: COMPARATOR
Intervention: MGL-3196 (200 mg per day)
Number of subjects: 0
Study 22144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine 1 μg/kg
Number of subjects: 120
Study 22144926 — intervention group
Group type: COMPARATOR
Intervention: Oral midazolam 0.5 mg/kg
Number of subjects: 120
Study 21330794 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography-guided (USG) placement
Number of subjects: 28
Study 21330794 — intervention group
Group type: COMPARATOR
Intervention: Traditional landmark method (no USG)
Number of subjects: 28
Study 17338683 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% polidocanol foam
Number of subjects: 80
Study 17338683 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% polidocanol foam
Number of subjects: 80
Study 15034814 — intervention group
Group type: EXPERIMENTAL
Intervention: Microcoblation
Number of subjects: 0
Study 15034814 — intervention group
Group type: COMPARATOR
Intervention: Microdermabrasion
Number of subjects: 0
Study 11411818 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 583
Study 11411818 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 583
Study 9474454 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3% ofloxacin eyedrops, BID
Number of subjects: 50
Study 9474454 — intervention group
Group type: COMPARATOR
Intervention: 0.3% ofloxacin eyedrops, QID
Number of subjects: 50
Study 7636050 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434 QD (10 mg loratadine + 240 mg pseudoephedrine sulfate)
Number of subjects: 874
Study 7636050 — intervention group
Group type: EXPERIMENTAL
Intervention: SCH 434 QD
Number of subjects: 874
Study 7636050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 874
Study 7636050 — intervention group
Group type: COMPARATOR
Intervention: Pseudoephedrine
Number of subjects: 874
Study 7636050 — intervention group
Group type: COMPARATOR
Intervention: Loratadine
Number of subjects: 874
Study 2198085 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen inhalation challenge
Number of subjects: 9
Study 2198085 — intervention group
Group type: COMPARATOR
Intervention: Diluent control
Number of subjects: 9
Study 2198085 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchoconstriction induced by methacholine
Number of subjects: 9
Study 63673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (1g/day)
Number of subjects: 40
Study 63673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31037454 — intervention group
Group type: EXPERIMENTAL
Intervention: Slower rate of infusion of etomidate
Number of subjects: 96
Study 31037454 — intervention group
Group type: COMPARATOR
Intervention: Standard induction dose of etomidate
Number of subjects: 96
Study 29099333 — intervention group
Group type: EXPERIMENTAL
Intervention: Tezacaftor-Ivacaftor
Number of subjects: 248